Cogent Biosciences, Inc. (COGT)

US — Healthcare Sector
Peers: LRMR  KURA  KNSA  CERE  IDYA  ANAB  MGTX  KROS  FIXX  SANA  OLMA  CGEM  LIFE  ZNTL  SNDX  KALV  MRSN  VTYX  PTGX  VRNA 

Automate Your Wheel Strategy on COGT

With Tiblio's Option Bot, you can configure your own wheel strategy including COGT - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.

Start Your Free Trial Now

Key Metrics & Ratings

  • symbol COGT
  • Rev/Share 0.0
  • Book/Share 1.9327
  • PB 2.8147
  • Debt/Equity 0.078
  • CurrentRatio 5.1276
  • ROIC -1.2219

 

  • MktCap 619376640.0
  • FreeCF/Share -1.9665
  • PFCF -2.7797
  • PE -2.2872
  • Debt/Assets 0.0602
  • DivYield 0
  • ROE -0.9268

 

  • Rating C
  • Score 2
  • Recommendation Sell
  • P/E Score 1
  • DCF Score 3
  • P/B Score 2
  • D/E Score 3

Recent Analyst Ratings

Type Ticker Analyst Firm Previous Rating Current Rating Previous Price Target Current Price Target Date
Initiation COGT Scotiabank -- Sector Outperform -- $17 March 7, 2025
Downgrade COGT Needham Buy Hold -- -- Dec. 11, 2024

News

Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade
COGT
Published: May 13, 2025 by: Zacks Investment Research
Sentiment: Positive

The consensus price target hints at a 224.4% upside potential for Cogent Biosciences (COGT). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Read More
image for news Wall Street Analysts Believe Cogent Biosciences (COGT) Could Rally 224.37%: Here's is How to Trade
Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
COGT
Published: February 27, 2025 by: GlobeNewsWire
Sentiment: Neutral

65% mean improvement in Total Symptom Score (TSS) at 48 weeks, including 88% of patients achieving at least a 50% reduction in TSS Top-line results from Summit Part 2 registration-directed trial on track for July 2025 WALTHAM, Mass. and BOULDER, Colo.

Read More
image for news Cogent Biosciences Announces SUMMIT Continues to Showcase Powerful Symptomatic Improvement in NonAdvanced Systemic Mastocytosis Patients
Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
COGT
Published: February 25, 2025 by: GlobeNewsWire
Sentiment: Neutral

• Top-line results from SUMMIT trial in NonAdvSM patients expected July 2025 • APEX trial enrollment in AdvSM patients complete; top-line results expected in 2H 2025 • Top-line results from PEAK trial in 2 nd -line GIST patients expected by end of 2025 • $312 million sufficient to fund operations well past clinical readouts, into late 2026; includes gross proceeds from ATM sale in February 2025 WALTHAM, Mass. and BOULDER, Colo.

Read More
image for news Cogent Biosciences Reports Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results

About Cogent Biosciences, Inc. (COGT)

  • IPO Date 2018-03-29
  • Website https://www.cogentbio.com
  • Industry Biotechnology
  • CEO Mr. Andrew R. Robbins M.B.A.
  • Employees 205

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes CGT9486, a selective tyrosine kinase inhibitor designed to inhibit the KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. It has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.